BSEAuro Laboratories LtdMediumPositive
Announced Tue, 5 May · 19:15 IST

Auro Laboratories Limited submits that the Company has received a "Certification of Substances Department" from the European Directorate for the Quality of Medicines & Healthcare ("EDQM") ....

Regulatory Product ApprovalBusiness Updates View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+5.7%1-day move
₹249.75
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+5.7+8.1+4.1+7.2+8.0+7.3+8.1+1.3+0.7
Up moveDown movePending
AI summary

Auro Laboratories Limited has received an Attestation of Inspection from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its manufacturing facility at MIDC Tarapur, Maharashtra. The certification confirms compliance with EU Good Manufacturing Practice (GMP) requirements for Metformin Hydrochloride (CEP Dossier No. CEP 2005-123). The inspection reference number is INSP 2012-002-P05. This is a regulatory certification that validates the quality standards of the company's pharmaceutical manufacturing facility.

Likely market impact

This GMP certification from EDQM enables Auro Laboratories to continue supplying Metformin Hydrochloride to European markets. It enhances the company's credibility as a quality-certified pharmaceutical ingredient manufacturer and removes a potential regulatory barrier for EU exports.